Professor of Medicine, University Mich Medical School
Oncology
Dr. Ronald B. Natale, MD
|
|
Give Review
Ronald Natale works in the field of Oncology. He researched medicine at Wayne State University School of Medicine. Wayne State University School of Medicine is ranked 63 in research and 85 in primary care medicine He over the years received 6 awards: "America's Top Doctors", "Top Doctors:LA Area", "America's Top Doctors for Cancer", "Top Doctors:Southern California", "Whos Who in Medicine and Healthcare" and "Super Doctor". Ronald Natale has written publications. He has 33 publications published with PubMed. The lastest paper is: 'Evaluation of Antitumor Activity Using Change in Tumor Size of the Survivin Antisense Oligonucleotide LY2181308 in Combination with Docetaxel for Second-Line Treatment...' Doctor Ronald B. Natale, MD accepts Medicare payments and is listed with Medicare.gov.
Publications
- Evaluation of Antitumor Activity Using Change in Tumor Size of the Survivin Antisense Oligonucleotide LY2181308 in Combination with Docetaxel for Second-Line Treatment...
- Pharmacokinetic study of aldoxorubicin in patients with solid Tumors.
- Phase II study of sunitinib as maintenance therapy in patients with locally advanced or metastatic non-small cell lung Cancer.
- Phase III trial of vandetanib compared with erlotinib in patients with previously treated advanced non-small-cell lung Cancer.
- Do mixed histological features affect survival benefit from neoadjuvant platinum-based combination chemotherapy in patients with locally advanced bladder Cancer? A sec...
- Quality of pathologic response and surgery correlate with survival for patients with completely resected bladder Cancer after neoadjuvant chemotherapy.
- Vandetanib versus gefitinib in patients with advanced non-small-cell lung Cancer: results from a two-part, double-blind, randomized phase ii study.
- Baseline vascular endothelial growth factor concentration as a potential predictive marker of benefit from vandetanib in non-small cell lung Cancer.
- Dual targeting of the vascular endothelial growth factor receptor and epidermal growth factor receptor pathways with vandetinib (ZD6474) in patients with advanced or m...
- Summary statement novel agents in the treatment of lung Cancer: Fifth Cambridge Conference assessing opportunities for combination therapy.
- Efficacy and safety of single-agent pertuzumab, a human epidermal receptor dimerization inhibitor, in patients with non small cell lung Cancer.
- Randomized phase III trial of cisplatin/irinotecan versus cisplatin/etoposide in patients with extensive-stage small-cell lung Cancer.
- The emerging role of vascular endothelial growth factor receptor tyrosine kinase inhibitors.
- Epithelial membrane protein-1 is a biomarker of gefitinib resistance.
- Clinically meaningful improvement in symptoms and quality of life for patients with non-small-cell lung Cancer receiving gefitinib in a randomized controlled trial.
- Phase I clinical study of pertuzumab, a novel HER dimerization inhibitor, in patients with advanced Cancer.
- Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic Cancer.
- Surgical factors influence bladder Cancer outcomes: a cooperative group report.
- Gemcitabine-containing regimens vs others in first-line treatment of NSCLC.
- Effects of ZD1839 (Iressa, gefitinib) treatment on symptoms and quality of life in patients with advanced non-small cell lung Cancer.
- Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung Cancer: a phase III trial--INTACT 1.
- Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung Cancer: a phase III trial--INTACT 2.
- Epidermal growth factor receptor-targeted therapy with ZD1839: symptom improvement in non-small-cell lung Cancer.
- Inhibition of epidermal growth factor receptor and symptom improvement in advanced non-small cell lung Cancer.
- Estimating the impact of new clinical trial proven Cancer therapy and Cancer chemoprevention on population mortality: the Karnofsky Memorial lecture.
- Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung Cancer: a randomized trial.
- Biologically targeted treatment of non-small-cell lung Cancer: focus on epidermal growth factor receptor.
- Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder Cancer.
- Irinotecan, cisplatin/carboplatin, and COX-2 inhibition in small-cell lung Cancer.
- Phase II trial of irinotecan, paclitaxel and carboplatin in patients with previously untreated Stage IIIB/IV nonsmall cell lung Carcinoma.
- Gemcitabine-based doublets for advanced non-small-cell lung Cancer: beyond gemcitabine/cisplatin.
- ZD1839 (Iressa): what's in it for the patient?
Schools
Wayne State University School Of Medicine
Wayne State University Affil Hosps P
Meml Sloan Kettering
Procedures Preformed
- Thoracentesis
Conditions Treated
- Adrenal Gland Cancer
- Anemia
- Breast Cancer
- Carcinoma in Situ
- View All
Doctors Specialties
- Medical Oncology
- Oncology
Accepted Insurances
Awards
- America's Top Doctors
- Top Doctors:LA Area
- America's Top Doctors for Cancer
- Top Doctors:Southern California
- Whos Who in Medicine and Healthcare
- Super Doctor
Education
-
Memorial Sloan-Kettering Cancer Center -
Wayne State University School of Medicine
Hospital
-
Ronald Reagan UCLA Medical Center -
Cedars-Sinai Medical Center
Drug Facts
| NPI NUMBER | 1285734350 | |
| NPPES Provider LastName | NATALE | |
| NPPES Provider FirstName | RONALD | |
| NPPES Provider ZIPCode | 900481804 | |
| NPPES Provider State | CA | |
| Specialty Description | Medical Oncology | |
| Total Claim Count | 566.0 | |
| Distinct Opioid Count | 1.0 | |
| Opioid Claim Count | 21.0 | |
| Percent Opioid Claims | 3.71 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1285734350 |
| Last Name Of The Provider | NATALE |
| First Name Of The Provider | RONALD |
| View All |
Similar Doctors
|
|
Dr. Edward M. Wolin, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. James R. Berenson, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Daphne B. Stewart, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Gregory P. Sarna, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. William M. Audeh, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Michael B. Engelberg, MD
This Doctor is OpenDoctor Recommended.
|